This company listing is no longer active
2257 Stock Overview
An RNA therapeutics biopharmaceutical company, discovers and develops product candidates for indications with medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Sirnaomics Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$3.11 |
| 52 Week High | HK$54.25 |
| 52 Week Low | HK$2.49 |
| Beta | -0.39 |
| 11 Month Change | -21.27% |
| 3 Month Change | -48.93% |
| 1 Year Change | -93.72% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -94.20% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2257 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | -5.5% | 18.3% | 8.7% |
| 1Y | -93.7% | 1.9% | 19.7% |
Return vs Industry: 2257 underperformed the Hong Kong Biotechs industry which returned -20.6% over the past year.
Return vs Market: 2257 underperformed the Hong Kong Market which returned -3.3% over the past year.
Price Volatility
| 2257 volatility | |
|---|---|
| 2257 Average Weekly Movement | 12.5% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in HK Market | 14.7% |
| 10% least volatile stocks in HK Market | 3.6% |
Stable Share Price: 2257's share price has been volatile over the past 3 months.
Volatility Over Time: 2257's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 90 | Alan Patrick Lu | www.sirnaomics.com |
Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops product candidates for indications with medical needs. The company’s therapeutics products focus on oncology and fibrosis, anticoagulant therapies, cardiometabolic disease, complement-mediated diseases, medical aesthetics, and viral infections. Its lead drug candidates include STP705 for the treatment of non-melanoma skin cancer and for focal fat reduction; and STP707 to treat solid tumors.
Sirnaomics Ltd. Fundamentals Summary
| 2257 fundamental statistics | |
|---|---|
| Market cap | HK$270.00m |
| Earnings (TTM) | -HK$637.90m |
| Revenue (TTM) | HK$8.41m |
32.1x
P/S Ratio-0.4x
P/E RatioIs 2257 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2257 income statement (TTM) | |
|---|---|
| Revenue | US$1.08m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.08m |
| Other Expenses | US$82.88m |
| Earnings | -US$81.80m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.94 |
| Gross Margin | 100.00% |
| Net Profit Margin | -7,587.85% |
| Debt/Equity Ratio | -2.4% |
How did 2257 perform over the long term?
See historical performance and comparison